Septerna (NASDAQ:SEPN) Trading 2.4% Higher - Here's Why

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares traded up 2.4% on Friday . The stock traded as high as $13.94 and last traded at $13.88. 202,547 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 302,506 shares. The stock had previously closed at $13.56.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald lifted their price objective on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Wells Fargo & Company upped their price target on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research note on Friday, May 16th. Finally, HC Wainwright assumed coverage on shares of Septerna in a research note on Monday, June 23rd. They set a "buy" rating and a $26.00 price target on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Septerna currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Trading Up 2.4%

The stock has a fifty day simple moving average of $10.83 and a two-hundred day simple moving average of $9.82.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The business had revenue of $0.22 million during the quarter. As a group, equities research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SEPN. Charles Schwab Investment Management Inc. purchased a new position in Septerna during the 4th quarter valued at about $3,197,000. Vanguard Group Inc. bought a new stake in shares of Septerna during the 4th quarter valued at about $22,557,000. Corebridge Financial Inc. bought a new stake in shares of Septerna during the 4th quarter valued at about $212,000. JPMorgan Chase & Co. bought a new stake in shares of Septerna during the 4th quarter valued at about $871,000. Finally, Geode Capital Management LLC bought a new stake in shares of Septerna during the 4th quarter valued at about $8,717,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.